AcuraBio expands cGMP plasmid DNA CDMO services with Cytiva’s latest single-use purification technology to alleviate supply constraints for mRNA and cell & gene therapies
-
AcuraBio selects Cytiva’s latest two-step purification protocol to offer its customers worldwide a productive plasmid DNA service and alleviate supply shortages for mRNA and cell and gene therapies
-
Latest purification technology provides efficient processing time for plasmid DNA production
Brisbane, Australia, February 10, 2023 /PRNewswire/ — AcuraBio, a leading Australian biopharmaceutical contract development and manufacturing company (CDMO), will offer a cGMP plasmid DNA CDMO service to the world using Cytiva’s new process platform technology.
AcuraBio expects to produce more plasmid DNA for its customers around the world using Cytiva’s latest two-step bacterial plasmid purification protocol. The new protocol features a single-use purification technology that offers efficiency, a high-purity outcome, and a sustainable process.[1]
Guillaume HerryAcuraBio CEO, says, “We are very excited to implement Cytiva’s latest technology, particularly as access to and production of plasmid DNA has been a bottleneck in the advanced therapy market. We intend to provide biotech and biopharmaceutical companies with higher quality plasmid DNA, faster than before, to support the development of new therapies such as viral vectors and mRNA.”
Jon Incemanaging director, commercial, Australia And New ZealandCytiva, says, “The introduction of Cytiva’s FlexFactory configurable manufacturing line within AcuraBio’s assets will enable AcuraBio to advance and better serve its customers based on efficient and flexible cGMP manufacturing services that meet the increasing demand for high quality therapeutics serve Australia And New Zealand region and beyond.”
According to Research and Markets, the size of the plasmid DNA manufacturing market is estimated $525.12 million in 2022 and is expected to experience a CAGR of 13.87% from 2023 to 2033. A growing public understanding of cell and gene therapy and the increasing number of patients choosing gene therapy as their treatment of choice are factors contributing to the market growth.[2]
To learn more about plasmid DNA technology, please visit the Biotech Makers webinar.
|
[1] Resources for calculated benefits for the 200L scale pDNA downstream process |
|
|
[2] Plasmid DNA Manufacturing Global Market Report 2022: Increasing Number of Patients Choosing Gene Therapy as Their Treatment to Boost Growth |
About AcuraBio
AcuraBio Pty Ltd is one of them Australia most experienced biopharmaceutical CDMOs who have been providing trusted, customer-centric services to national and international clients for 20 years. AcuraBio provides significant quality, cost and IP assurances to biopharmaceutical companies around the world. World-class researchers and proven institutions, a tight regulatory framework, generous tax incentives and government funding Australia a prime location for biotechnological research. AcuraBio holds the following operating licenses: TGA license (Australian FDA equivalent) to manufacture human therapeutic APIs from biological and synthetic sources, APVMA license (veterinary equivalent of TGA) to manufacture sterile immunobiological products, OGTR license to manufacture Products modified organisms from genetic sources and a DAF operating license to import and use biological materials. For more information about AcuraBio, visit www.AcuraBio.com.
About Cytiva
At Cytiva, we believe the key to transforming human health lies in access to life-changing therapies. That’s why our nearly 10,000 employees in more than 40 countries are focused on helping researchers, biopharmaceutical companies, and drugmakers advance and accelerate therapeutics for people who need them. We are driven by their desire for more flexibility, capacity and efficiency in all facets of their work – from discovery to delivery. Learn more at cytiva.com.
Media contact:
Acura Bio
[email protected]
Cytiva
Iris Zhao
[email protected]
SOURCE AcuraBio; Cytiva